Last reviewed · How we verify

NCT04527939

Analysis of Extraperitoneal Rectal Neoplasms Between 3D Endorectal Ultrasonography and Magnification Chromoendoscopy

Status unknown NA Last updated 27 August 2020
What this trial tests

NA trial testing three-dimensional endorectal ultrasonography in Rectal Cancer in 70 participants. Status unknown.

Timeline
7 August 2020
Primary endpoint
10 August 2020
7 August 2023

Quick facts

Lead sponsorUniversity of Sao Paulo
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment70
Start date7 August 2020
Primary completion10 August 2020
Estimated completion7 August 2023
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

University of Sao Paulo

Who can join

Adults 18 to 75, any sex, with Rectal Cancer or Rectal Cancer Stage I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ERUS-3D and CMI demonstrated good diagnostic accuracy in parietal staging of rectal extraperitoneal neoplasms, however with greater efficiency of the endoscopic method. The association of studies can improve diagnostic efficacy and influence the most appropriate approach.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

Other University of Sao Paulo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04527939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing